The Pharma Data
NOVEMBER 9, 2020
Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). Next Steps in Immunotherapy.
NIH Director's Blog: Drug Development
MARCH 18, 2021
Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. And, how can those structural differences serve as blueprints for promising new treatments to combat many potentially deadly viruses?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
MAY 21, 2020
Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. References : [1] Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. In the U.S.
The Pharma Data
OCTOBER 19, 2020
The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response. NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy.
Drug Target Review
FEBRUARY 28, 2024
Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. from 2003 to 2006, covering the biotechnology and life-science tools sectors. gammadelta T cells link innate and adaptive immune responses. J Exp Med 198(5):747-755 (2003). References Fichtner A, Ravens S, Prinz I.
Drug Target Review
OCTOBER 4, 2023
Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
Expert insights. Personalized for you.
40 
Let's personalize your content